Heartflow Stock (NASDAQ:HTFL)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$27.72

52W Range

$20.13 - $41.22

50D Avg

$30.12

200D Avg

$29.89

Market Cap

$2.30B

Avg Vol (3M)

$1.49M

Beta

1.92

Div Yield

-

HTFL Company Profile


HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.

Show More

Industry

Medical - Healthcare Information Services

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

843

IPO Date

Aug 07, 2025

Website

HTFL Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25
Non Us$13.30M

Fiscal year ends in Dec 25 | Currency in USD

HTFL Financial Summary


Dec 25Dec 24Dec 23
Revenue$176.03M$125.81M$87.17M
Operating Income$-64.07M$-61.22M$-72.91M
Net Income$-116.79M$-96.43M$-95.66M
EBITDA$-64.07M$-65.47M$-62.83M
Basic EPS$-3.17$-1.49$-1.94
Diluted EPS$-3.17$-1.49$-1.94

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison


TickerCompany
IRONDisc Medicine, Inc.
PRGOPerrigo Company plc
ATECAlphatec Holdings, Inc.
TARSTarsus Pharmaceuticals, Inc.
TVTXTravere Therapeutics, Inc.
SGRYSurgery Partners, Inc.
LIVNLivaNova PLC
PRVAPrivia Health Group, Inc.
ZLABZai Lab Limited
LEGNLegend Biotech Corporation